News for Peptron, Inc. (087010.KQ)

Prominent somatostatin analogs market players include Sun Pharmaceutical Industries Limited, Novartis AG, Biodexa Pharmaceuticals PLC, Ipsen Pharma, Pfizer...

/PRNewswire/ -- Peptron, Inc. (KOSDAQ: 087010), ein führendes Unternehmen in der Entwicklung von peptidbasierten Arzneimitteln mit verzögerter Freisetzung, gab...

/PRNewswire/ -- Peptron, Inc. (KOSDAQ: 087010), une société leader dans le développement de médicaments à libération prolongée à base de peptides, a annoncé le...

Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has randomised the first idiopathic intracranial hypertension (IIH) patient into its IIH Evolve Phase III clinical trial using lead drug Presendin.

The dementia drugs market is expected to expand due to the rising prevalence of dementia and neurological disorders, such as vascular dementia, along with...

DelveInsight’s “Parkinson’s Disease Pipeline Insight” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the...

Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has confirmed it will proceed with a single, Phase III clinical trial to achieve global registration of lead drug Presendin in the treatment of idiopathic intracranial hypertension (IIH).

A hamster in the US has a portfolio up by around 20% since June, outpacing the S&P500 and Warren Buffett's Berkshire Hathaway.

ASX health stock Invex Therapeutics jumped 14% today after signing an exclusive long term agreement with Korean-listed Peptron Inc.